Summary & Overview
HCPCS Level II J0834: Cosyntropin 0.25 mg Injection
HCPCS Level II code J0834 denotes a 0.25 mg injection of cosyntropin used primarily for diagnostic adrenal stimulation testing. The code captures administration of a pharmacologic agent that aids in diagnosing adrenal insufficiency and related endocrine disorders. Nationally, accurate coding of J0834 matters for appropriate clinical documentation, claims processing, and consistency in reporting diagnostic endocrine procedures.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of billing and clinical context for J0834, including benchmarks where available, payer coverage patterns, common billing modifiers, and operational considerations for sites that commonly administer diagnostic injections. The publication highlights policy-relevant items such as coverage clarification and coding guidance rather than clinical guidance.
This summary is intended for revenue cycle professionals, clinical staff involved in endocrine testing, and policy analysts seeking a national perspective on how J0834 is used and reimbursed across major payers. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0834 represents an injection of cosyntropin, 0.25 mg. This product is used for diagnostic testing of adrenal insufficiency and stimulation testing of the hypothalamic-pituitary-adrenal axis.
-
Service type: Diagnostic injection
-
Typical site of service: Outpatient clinic, hospital outpatient department, or clinical laboratory setting where endocrine diagnostic testing is performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient infusion clinic or emergency department for evaluation of suspected adrenal insufficiency or for assessment of hypothalamic-pituitary-adrenal (HPA) axis function. The patient frequently has symptoms such as unexplained fatigue, hypotension, weight loss, abdominal pain, or orthostatic dizziness, or there is concern for secondary adrenal insufficiency after pituitary surgery or prolonged steroid taper. The ordered diagnostic test is an ACTH stimulation test using J0834 (cosyntropin, 0.25 mg) administered intramuscularly or intravenously.
The clinical workflow: the clinician documents indications and obtains informed consent; baseline vital signs and baseline serum cortisol (and sometimes plasma ACTH) are drawn; a nurse or licensed professional administers J0834 per protocol (commonly 250 mcg cosyntropin IV/IM); timed post‑dose cortisol samples are obtained (commonly at 30 and 60 minutes); samples are sent to the lab and results are interpreted by the ordering clinician to confirm or exclude adrenal insufficiency. Billing for J0834 is reported for the cosyntropin drug administered; separate billing may occur for laboratory assays, venipuncture, and evaluation and management services as clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|